The reliability of high-risk human papillomavirus detection by Aptima HPV assay in women with ASC-US cytology

Philip E. Castle, Jennifer Reid, Janel Dockter, Damon Getman

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: The Aptima HPV assay (AHPV) for high-risk human papillomavirus (hrHPV), and the Aptima HPV 16 18/45 Genotype assay (AHPV GT) for HPV16 and for HPV18 and/or HPV45 (HPV18/45) genotypes are approved for cervical cancer screening by the U.S. Food and Drug Administration. There are limited data on the reliability of these tests for detection of hrHPV, HPV16, and HPV18/45. Objectives: To assess the reliability of AHPV and AHPV GT on paired specimens from women with atypical squamous cells of undetermined significance (ASC-US) cytology. Study design: In a population of women with ASC-US cytology (n= 988), cervical specimens were collected at a routine screening baseline visit and at the colposcopy visit that occurred a median of 29 days later. Specimens were tested by AHPV and if positive, by AHPV GT. Results: There was no significant difference in the percent AHPV positive between the colposcopy and baseline specimens (41.9% vs. 43.0%, respectively, p= 0.3). The percent agreement, percent positive agreement, and the kappa value were 88.6%, 76.3%, and 0.766, respectively. There were no significant differences between AHPV testing of the colposcopy and baseline specimen in the sensitivity (95.2% vs. 92.9%, respectively, p= 1) and specificity (60.5% vs. 59.2%, respectively, p= 0.3) for CIN3+ Comparing the hierarchical AHPV and AHPV GT results on the two specimens, the percent exact agreement was 86.2%, the percent positive agreement was 68.4%, and the kappa value was 0.746. Conclusions: AHPV and AHPV GT demonstrated good reliability for hrHPV detection and risk stratification.

Original languageEnglish (US)
Pages (from-to)52-55
Number of pages4
JournalJournal of Clinical Virology
Volume69
DOIs
StatePublished - Aug 1 2015

Fingerprint

Colposcopy
Cell Biology
Genotype
Human papillomavirus 18
Human papillomavirus 16
United States Food and Drug Administration
Early Detection of Cancer
Uterine Cervical Neoplasms
Atypical Squamous Cells of the Cervix
Population

Keywords

  • Atypical squamous cells of undetermined significance (ASC-US)
  • Cervical cancer
  • Cervical intraepithelial neoplasia (CIN)
  • Human papillomavirus (HPV)
  • Pap

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology

Cite this

The reliability of high-risk human papillomavirus detection by Aptima HPV assay in women with ASC-US cytology. / Castle, Philip E.; Reid, Jennifer; Dockter, Janel; Getman, Damon.

In: Journal of Clinical Virology, Vol. 69, 01.08.2015, p. 52-55.

Research output: Contribution to journalArticle

@article{c2d5a37d4f71462baf76755ce599887a,
title = "The reliability of high-risk human papillomavirus detection by Aptima HPV assay in women with ASC-US cytology",
abstract = "Background: The Aptima HPV assay (AHPV) for high-risk human papillomavirus (hrHPV), and the Aptima HPV 16 18/45 Genotype assay (AHPV GT) for HPV16 and for HPV18 and/or HPV45 (HPV18/45) genotypes are approved for cervical cancer screening by the U.S. Food and Drug Administration. There are limited data on the reliability of these tests for detection of hrHPV, HPV16, and HPV18/45. Objectives: To assess the reliability of AHPV and AHPV GT on paired specimens from women with atypical squamous cells of undetermined significance (ASC-US) cytology. Study design: In a population of women with ASC-US cytology (n= 988), cervical specimens were collected at a routine screening baseline visit and at the colposcopy visit that occurred a median of 29 days later. Specimens were tested by AHPV and if positive, by AHPV GT. Results: There was no significant difference in the percent AHPV positive between the colposcopy and baseline specimens (41.9{\%} vs. 43.0{\%}, respectively, p= 0.3). The percent agreement, percent positive agreement, and the kappa value were 88.6{\%}, 76.3{\%}, and 0.766, respectively. There were no significant differences between AHPV testing of the colposcopy and baseline specimen in the sensitivity (95.2{\%} vs. 92.9{\%}, respectively, p= 1) and specificity (60.5{\%} vs. 59.2{\%}, respectively, p= 0.3) for CIN3+ Comparing the hierarchical AHPV and AHPV GT results on the two specimens, the percent exact agreement was 86.2{\%}, the percent positive agreement was 68.4{\%}, and the kappa value was 0.746. Conclusions: AHPV and AHPV GT demonstrated good reliability for hrHPV detection and risk stratification.",
keywords = "Atypical squamous cells of undetermined significance (ASC-US), Cervical cancer, Cervical intraepithelial neoplasia (CIN), Human papillomavirus (HPV), Pap",
author = "Castle, {Philip E.} and Jennifer Reid and Janel Dockter and Damon Getman",
year = "2015",
month = "8",
day = "1",
doi = "10.1016/j.jcv.2015.05.006",
language = "English (US)",
volume = "69",
pages = "52--55",
journal = "Journal of Clinical Virology",
issn = "1386-6532",
publisher = "Elsevier",

}

TY - JOUR

T1 - The reliability of high-risk human papillomavirus detection by Aptima HPV assay in women with ASC-US cytology

AU - Castle, Philip E.

AU - Reid, Jennifer

AU - Dockter, Janel

AU - Getman, Damon

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Background: The Aptima HPV assay (AHPV) for high-risk human papillomavirus (hrHPV), and the Aptima HPV 16 18/45 Genotype assay (AHPV GT) for HPV16 and for HPV18 and/or HPV45 (HPV18/45) genotypes are approved for cervical cancer screening by the U.S. Food and Drug Administration. There are limited data on the reliability of these tests for detection of hrHPV, HPV16, and HPV18/45. Objectives: To assess the reliability of AHPV and AHPV GT on paired specimens from women with atypical squamous cells of undetermined significance (ASC-US) cytology. Study design: In a population of women with ASC-US cytology (n= 988), cervical specimens were collected at a routine screening baseline visit and at the colposcopy visit that occurred a median of 29 days later. Specimens were tested by AHPV and if positive, by AHPV GT. Results: There was no significant difference in the percent AHPV positive between the colposcopy and baseline specimens (41.9% vs. 43.0%, respectively, p= 0.3). The percent agreement, percent positive agreement, and the kappa value were 88.6%, 76.3%, and 0.766, respectively. There were no significant differences between AHPV testing of the colposcopy and baseline specimen in the sensitivity (95.2% vs. 92.9%, respectively, p= 1) and specificity (60.5% vs. 59.2%, respectively, p= 0.3) for CIN3+ Comparing the hierarchical AHPV and AHPV GT results on the two specimens, the percent exact agreement was 86.2%, the percent positive agreement was 68.4%, and the kappa value was 0.746. Conclusions: AHPV and AHPV GT demonstrated good reliability for hrHPV detection and risk stratification.

AB - Background: The Aptima HPV assay (AHPV) for high-risk human papillomavirus (hrHPV), and the Aptima HPV 16 18/45 Genotype assay (AHPV GT) for HPV16 and for HPV18 and/or HPV45 (HPV18/45) genotypes are approved for cervical cancer screening by the U.S. Food and Drug Administration. There are limited data on the reliability of these tests for detection of hrHPV, HPV16, and HPV18/45. Objectives: To assess the reliability of AHPV and AHPV GT on paired specimens from women with atypical squamous cells of undetermined significance (ASC-US) cytology. Study design: In a population of women with ASC-US cytology (n= 988), cervical specimens were collected at a routine screening baseline visit and at the colposcopy visit that occurred a median of 29 days later. Specimens were tested by AHPV and if positive, by AHPV GT. Results: There was no significant difference in the percent AHPV positive between the colposcopy and baseline specimens (41.9% vs. 43.0%, respectively, p= 0.3). The percent agreement, percent positive agreement, and the kappa value were 88.6%, 76.3%, and 0.766, respectively. There were no significant differences between AHPV testing of the colposcopy and baseline specimen in the sensitivity (95.2% vs. 92.9%, respectively, p= 1) and specificity (60.5% vs. 59.2%, respectively, p= 0.3) for CIN3+ Comparing the hierarchical AHPV and AHPV GT results on the two specimens, the percent exact agreement was 86.2%, the percent positive agreement was 68.4%, and the kappa value was 0.746. Conclusions: AHPV and AHPV GT demonstrated good reliability for hrHPV detection and risk stratification.

KW - Atypical squamous cells of undetermined significance (ASC-US)

KW - Cervical cancer

KW - Cervical intraepithelial neoplasia (CIN)

KW - Human papillomavirus (HPV)

KW - Pap

UR - http://www.scopus.com/inward/record.url?scp=84937856164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937856164&partnerID=8YFLogxK

U2 - 10.1016/j.jcv.2015.05.006

DO - 10.1016/j.jcv.2015.05.006

M3 - Article

C2 - 26209379

AN - SCOPUS:84937856164

VL - 69

SP - 52

EP - 55

JO - Journal of Clinical Virology

JF - Journal of Clinical Virology

SN - 1386-6532

ER -